InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline. Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services,...
It is well-established that syngeneic mouse models represent a powerful tool to evaluate therapies that target the immune system. The key to understanding your immuno-modulatory compound’s efficacy is to work with well-characterised models, with known growth...
July is Fragile X Syndrome (FXS) Awareness month, a time dedicated to raising awareness about this rare genetic disorder, affecting thousands of individuals worldwide. We are deeply committed to accelerating the availability of targeted therapies to improve the lives...
September is STXBP1 disorders awareness month, an initiative aimed at raising awareness of STXBP1-related rare genetic disorders, such as epileptic encephalopathy. Although STXBP1-related disorders are rare; STXBP1 is the 5th most common cause of genetic forms of...
While the so-called Western-style diets largely contribute to metabolic dysfunction observed in patients with overweight or obesity, type 2 diabetes mellitus and/or NASH, the current epidemiological evidence suggests that increased consumption of Western-style diets...